Results 31 to 40 of about 1,579,650 (291)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer

open access: yesFrontiers in Immunology, 2022
The immune checkpoint pathway consisting of the cell membrane-bound molecule programmed death protein 1 (PD-1) and its ligand PD-L1 has been found to mediate negative regulatory signals that effectively inhibit T-cell proliferation and function and ...
Mengke Niu   +5 more
doaj   +1 more source

PD-L1 blockade after XVir-N-31-anti-PD-L1 infection.pzfx

open access: yes, 2022
PD-L1 blockade assay 
Moritz Klawitter (13177230)
core   +1 more source

Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients

open access: yesJournal of the Egyptian National Cancer Institute, 2018
Cancer immunotherapy targeting programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway has shown promising results in treatment of non-small cell lung cancer (NSCLC) patients.
Dina M. El-Guindy   +3 more
doaj   +1 more source

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma

open access: yesDiagnostics, 2020
Recent data have suggested that PD-1 and PD-L1 are involved in osteosarcoma (OS) pathogenesis; however, their contributions are not well-established. Here, the PD-1/PD-L1 expression was evaluated in (OS) cases.
Kazuhiko Hashimoto   +2 more
doaj   +1 more source

Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer

open access: yesCell Death and Disease, 2021
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated.
Min Liu   +9 more
doaj   +1 more source

Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display

open access: yes, 2022
Therapeutic monoclonal antibodies directed against PD-L1 (e.g., atezolizumab) disrupt PD-L1:PD-1 signaling and reactivate exhausted cytotoxic T-cells in the tumor compartment.
Brian J. Grindel (9407114)   +10 more
core   +1 more source

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1

open access: yesJournal of Translational Medicine, 2020
Background Previous studies have shown clinical relevance of programmed death-ligand 1 (PD-L1) and soluble PD-L1 (sPD-L1) in human cancers. However, still contradictory results exist.
Karolina Okła   +8 more
doaj   +1 more source

PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival [PDF]

open access: yesPigment Cell & Melanoma Research, 2018
AbstractThe aim of this study is to determine the significance of programmed death ligand 1 (PD‐L1 or CD274) methylation in relation to PD‐L1 expression and survival in melanoma. Despite the clinical importance of therapies targeting the PD‐1/PD‐L1 immune checkpoint in melanoma, factors regulating PD‐L1 expression, including epigenetic mechanisms, are ...
Goran Micevic   +3 more
openaire   +2 more sources

PD-L1 blockade enhances anti-tumor efficacy of NK cells

open access: yesOncoImmunology, 2018
Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors.
Jeremiah L. Oyer   +3 more
doaj   +1 more source

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

open access: yesBiomedicines, 2021
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy